Shepherd J
Institute of Biochemistry, Royal Infirmary, Glasgow, United Kingdom.
Am J Cardiol. 1995 Sep 28;76(9):113C-117C. doi: 10.1016/s0002-9149(99)80480-9.
The West of Scotland Coronary Prevention Study is a primary prevention trial designed to test the hypothesis that reduction of serum cholesterol with pravastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) over an average of 5 years will reduce the incidence of fatal and nonfatal myocardial infarction. At entry, 6,595 men aged 45-64 years were randomized to treatment with either pravastatin (40 mg/day) or placebo. None of the men at entry had evidence of previous myocardial infarction. All were given smoking and dietary advice throughout the study, which will terminate in 1995. The principal endpoints are: (1) death due to coronary artery disease (CAD) plus nonfatal myocardial infarction; (2) death due to CAD; and (3) nonfatal myocardial infarction.
苏格兰西部冠心病预防研究是一项一级预防试验，旨在验证以下假设：使用普伐他汀（一种3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）平均5年降低血清胆固醇水平，将减少致命和非致命性心肌梗死的发生率。入组时，6595名年龄在45至64岁的男性被随机分为接受普伐他汀（40毫克/天）治疗组或安慰剂组。入组时，所有男性均无既往心肌梗死的证据。在整个研究过程中，所有参与者都接受了关于吸烟和饮食的建议，该研究将于1995年结束。主要终点为：（1）冠状动脉疾病（CAD）导致的死亡加非致命性心肌梗死；（2）CAD导致的死亡；（3）非致命性心肌梗死。
